European registry Helicobacter pylori (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow

In order to evaluate the actual clinical practice of diagnosis and treatment of Helicobacter pylori and comparing it with the expert recommendations, the European Registry on the management of Helicobacter pylori infection (protocol "Hp-EuReg") started in 2013. An observational multicenter prospective study initiated by the European Helicobacter and Microbiota Study Group (EHMSG), with centers in 27 European countries. Materials and methods. The analysis of data of 647 patients enrolled in the Register by the A.S. Loginov Moscow Clinical Scientific Center, from 2013 to November 2019. The effectiveness of standard first-line triple therapy (amoxicillin, clarithromycin, a proton pump inhibitor) and standard triple therapy with bismuth tripotassium dicitrate was evaluated in 330 patients. Results. Invasive method is dominates in the initial diagnosis of H. pylori: the quick urease test, the frequency of administration of which decreased from 50% in 2013 to 31% in 2019. Serology has used in 27.9%. There has been an increase in the use of the C-13-urease breath test from 13% in 2013 to 31% in 2019. The histological method (7.5%) and the stool antigen test (3.2%) were used much less frequently. For eradication control has dominates non-invasive methods: C-13-UDT (82.7%) and the stool antigen test (14.4%). The effectiveness of standard triple therapy (ITT) was 68% with a 7-day course, 79% with a 10-day course, and 70% with a 14-day course. Combination of bismuth and standard triple therapy eradicates H. pylori (ITT) in 63%, 75% and 89%, respectively. Conclusion. An improvement in the clinical practice of managing patients with H. pylori infections has been noted. The standard triple therapy in combination with bismuth tripotassium dicitrate, prescribed for 14 days, is most effective.